Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer

Carcinogenesis

Volumn 30, Issue 11, 2009, Pages 1941-1948

  Chen, Yu Chi ^a   Sosnoski, Donna M ^a   Gandhi, Ujjawal H ^a   Novinger, Leah J ^a   Prabhu, K Sandeep ^a   Mastro, Andrea M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; CYCLOOXYGENASE 2; GLUTATHIONE PEROXIDASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PARTHENOLIDE; SELENIOUS ACID; SELENIUM; SELENOPROTEIN; SYNAPTOTAGMIN I;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BREAST CANCER; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOBLOTTING; INFLAMMATION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOKINE CCL2; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; ORGANOSELENIUM COMPOUNDS; OSTEOBLASTS; SELENIUM;

EID: 70849087652     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp227     Document Type: Article

References (50)

1. Guise,T.A. et al. (1998) Cancer and bone. Endocr. Rev., 19, 18-54.
2. Lipton,A. (2000) Bisphosphonates and breast carcinoma: Present and future. Cancer, 88, 3033-3037.
3. Delmas,P.D. et al. (1986) Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J. Clin. Invest., 77, 985-991.
4. Stewart,A.F. et al. (1982) Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: Uncoupling of bone cell activity. J. Clin. Endocrinol. Metab., 55, 219-227.
5. Mastro,A.M. et al. (2004) Breast cancer cells induce osteoblast apoptosis: A possible contributor to bone degradation. J. Cell. Biochem., 91, 265-276.
6. Mercer,R.R. et al. (2004) Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin. Exp. Metastasis, 21, 427-435.
7. Phadke,P.A. et al. (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin. Cancer Res., 12, 1431-1440.
8. Kinder,M. et al. (2008) Metastatic breast cancer induces an osteoblast inflammatory response. Exp. Cell Res., 314, 173-183.
9. Manolagas,S.C. (1995) Role of cytokines in bone resorption. Bone, 17, 63S-67S.
10. Balkwill,F. et al. (2004) Cancer: An inflammatory link. Nature 431, 405-406.
11. Fritz,E.A. et al. (2002) Titanium particles induce the immediate early stress responsive chemokines IL-8 and MCP-1 in osteoblasts. J. Orthop. Res., 20, 490-498.
12. Taranova,A.G. et al. (2008) Allergic pulmonary inflammation promotes the recruitment of circulating tumor cells to the lung. Cancer Res., 68, 8582-8589.
13. Baud,V. et al. (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov., 8, 33-40.
14. Zamamiri-Davis,F. et al. (2002) Nuclear factor-kappaB mediates overexpression of cyclooxygenase-2 during activation of RAW 264.7 macrophages in selenium deficiency. Free Radic. Biol. Med., 32 890-897.
15. Prabhu,K.S. et al. (2002) Selenium deficiency increases the expression of inducible nitric oxide synthase in RAW264.7 macrophages: role of nuclear factor-kappaB in up-regulation. Biochem. J., 366, 203-209.
16. Bjornstedt,M. et al. (1995) Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J. Biol. Chem., 270, 11761-11764.
17. Saito,Y. et al. (1999) Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein p. J. Biol. Chem., 274, 2866-2871.
18. Patrick,L. (2004) Selenium biochemistry and cancer: A review of the literature. Altern. Med. Rev., 9, 239-258.
19. Mantovani,G. et al. (2002) Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: Impact of an antioxidant treatment. J. Cell. Mol. Med., 6, 570-582.
20. Guven,M. et al. (1999) Lipid peroxidation and antioxidant system in the blood of cancerous patients with metastasis. Cancer Biochem. Biophys., 17, 155-162.
21. Roebuck,K.A. et al. (2001) Down-regulation of procollagen alpha1[I] messenger RNA by titanium particles correlates with nuclear factor kappaB (NF-kappaB) activation and increased rel A and NF-kappaB1 binding to the collagen promoter. J. Bone Miner Res., 16, 501-510.
22. Sudo,H. et al. (1983) In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol., 96, 191-198.
23. Cailleau,R. et al. (1974) Breast tumor cell lines from pleural effusions. J. Natl Cancer Inst., 53, 661-674.
24. Ip,C. et al. (2000) In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res., 60, 2882-2886.
25. Li,G.X. et al. (2008) Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis, 29, 1005-1012.
26. Haddad,J.J. (2002) Nuclear factor (NF)-kappa B blockade attenuates but does not abrogate LPS-mediated interleukin (IL)-1 beta biosynthesis in alveolar epithelial cells. Biochem. Biophys. Res. Commun., 293 252-257.
27. Hehner,S.P. et al. (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol., 163, 5617-5623.
28. Palempalli,U.D. et al. (2009) Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages. Biochem. J., 419, 401-409.
29. Vunta,H. et al. (2007) The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. J. Biol. Chem., 282, 17964-17973.
30. Paglia,D.E. et al. (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med., 70, 158-169.
31. Park,J.M. et al. (2007) Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis, 28, 837-847.
32. Jiang,C. et al. (2000) Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol. Carcinog., 29, 236-250.
33. Li,G.X. et al. (2007) Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int. J. Cancer, 120, 2034-2043.
34. Juliger,S. et al. (2007) Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Res., 67, 10984-10992.
35. Turan,B. et al. (2003) Selenium combined with vitamin E and vitamin C restores structural alterations of bones in heparin-induced osteoporosis. Clin. Rheumatol., 22, 432-436.
36. Moreno-Reyes,R. et al. (2001) Selenium deficiency-induced growth retardation is associated with an impaired bone metabolism and osteopenia. J. Bone Miner Res., 16, 1556-1563.
37. Tsukahara,H. et al. (1996) Selenium status and skeletal tissue metabolism in young infants. Eur. J. Pediatr., 155, 148-149.
38. Clark,L.C. et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963.
39. Combs,G.F.Jr et al. (2001) An analysis of cancer prevention by selenium. Biofactors, 14, 153-159.
40. Duffield-Lillico,A.J. et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev., 11, 630-639.
41. Lippman,S.M. et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 301, 39-51.
42. Kristal,A.R. (2008) Are clinical trials the "gold standard" for cancer prevention research? Cancer Epidemiol. Biomarkers Prev., 17, 3289-3291.
43. Rikiishi,H. (2007) Apoptotic cellular events for selenium compounds involved in cancer prevention. J. Bioenerg. Biomembr., 39, 91-98.
44. Suzuki,K.T. et al. (2006) Metabolic transformation of methylseleninic acid through key selenium intermediate selenide. Toxicol. Appl. Pharmacol., 215, 189-197.
45. Rodan,G.A. (2003) The development and function of the skeleton and bone metastases. Cancer, 97, 726-732.
46. Bussard,K.M. et al. (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev., 27, 41-55.
47. Yoneda,T. et al. (1993) Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res., 53, 737-740.
48. Aguirre-Ghiso,J.A. (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer, 7, 834-846.
49. Schardt,J.A. et al. (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell, 8, 227-239.
50. Karrison,T.G. et al. (1999) Dormancy of mammary carcinoma after mastectomy. J. Natl Cancer Inst., 91, 80-85.